Commonwealth Bank of Australia (OTCMKTS:CSLLY)’s stock price reached a new 52-week high on Tuesday . The company traded as high as $93.19 and last traded at $92.81, with a volume of 26311 shares traded. The stock had previously closed at $90.92.
Several equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of Commonwealth Bank of Australia from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised shares of Commonwealth Bank of Australia from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Jefferies Financial Group assumed coverage on shares of Commonwealth Bank of Australia in a research report on Monday, October 21st. They issued a “buy” rating for the company.
The company has a 50-day simple moving average of $85.00. The firm has a market capitalization of $82.37 billion, a P/E ratio of 43.06 and a beta of 0.68. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.14 and a current ratio of 2.53.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Further Reading: Should you buy a closed-end mutual fund?
Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.